

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	09/896,052
Filing Date	06/29/2001
First Named Inventor	BUNICK et al.
Group Art Unit	1615
Examiner Name	N/A
Attorney Docket Number	MCP-281

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,327,076		Puglia et al.	04/27/1982	
		4,684,534		Valentine	08/04/1987	
		4,828,845		Zamudio-Tena et al.	05/09/1989	
		4,851,226		Julian et al.	07/25/1989	
		5,075,114		Roche	12/24/1991	
		5,102,664		Day	04/07/1992	
		5,362,508		Wheeler et al.	11/08/1994	
		5,489,436		Hoy et al.	02/06/1996	
		5,618,527		Mendes et al.	04/08/1997	
		6,017,567		Rosenplenter	01/25/2000	
		6,077,557		Gordon et al.	06/20/2000	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		WO	93/13758	A1	Pfizer Inc.	07/22/1993		

Examiner Signature		Date Considered	8/13/02
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 28 2001

TECH CENTER 1600/2900

Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 2 of 2	<b>Application Number</b>	09/896,052
	<b>Filing Date</b>	06/29/2001
	<b>First Named Inventor</b>	BUNICK et al.
	<b>Group Art Unit</b>	1615
	<b>Examiner Name</b>	N/A
	<b>Attorney Docket Number</b>	MCP-281



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SO.		<i>Pharmaceutical Dosage Forms</i> ; Edited by Lieberman, H.A., Lachman, L., and Schwartz, J.B.; Marcel Dekker, Inc., New York, Vol. 1, pp. 285-328.	
		<i>Pharmaceutical Dosage Forms</i> ; Edited by Lieberman, H.A., Lachman, L., and Schwartz J.B.; Marcel Dekker, Inc., New York, Vol. 2, pp. 213-217 and 327-329.	
		<i>Pharmaceutical Dosage Forms</i> ; Edited by Lieberman, H.A., Lachman, L., Schwartz, J.B.; Marcel Dekker, Inc., New York, Vol. 3, pp.199-302.	
		<i>The Theory and Practice of Industrial Pharmacy</i> ; Lachman, L., Lieberman, H.A., Kanig, J.L.; Lea & Febiger, 3rd ed., 1986; pp. 293-345.	
		<i>Sugar Confectionery Manufacture</i> ; Edited by Jackson, E.B.; Van Nostrand Reinhold, New York, 1990, pp. 205-206.	

Examiner Signature	<i>Simon Oh</i>	Date Considered	8/13/02
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.